Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25684962 | 0.92 | TSHR (0.33) | KDM4ETSHRTDP1CYP1A2CYP2C19 | |
| SCHEMBL30095977 | 0.90 | TSHR (0.36) | KDM4ETSHRTDP1CYP1A2CYP2C19 | |
| SCHEMBL3919509 | 0.90 | TSHR (0.36) | KDM4ETSHRTDP1CYP1A2CYP2C19 | |
| SCHEMBL30096012 | 0.90 | TSHR (0.36) | KDM4ETSHRTDP1CYP1A2CYP2C19 | |
| SCHEMBL24421385 | 0.85 | — | — | |
| SCHEMBL25685339 | 0.85 | — | — | |
| SCHEMBL24421382 | 0.82 | — | — | |
| SCHEMBL25685471 | 0.80 | — | — | |
| SCHEMBL25761953 | 0.80 | — | — | |
| SCHEMBL10868933 | 0.79 | KDM4E (0.31) | KDM4ETSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070172646-A1 | Liquid resin composition, cured film and laminate | JSR CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1491562-B1 | FLUORINATED OLEFIN POLYMER, CURABLE RESIN COMPOSITION, AND ANTIREFLECTION FILM | JSR CORP (JP) | 2007-01-17 | — | — | EP | disclosed |
| EP-1624022-A1 | LIQUID RESIN COMPOSITION, CURED FILM AND LAMINATE | JSR Corporation (JP) | 2006-02-08 | — | — | EP | disclosed |
| US-20040209919-A1 | Stabilized pharmaceutical composition | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-10-21 | — | — | US | disclosed |
| US-6749864-B2 | BENZIMIDAZOLE ANTIULCER AGENTS STABILIZED BY INCORPORATION OF AN EFFECTIVE AMOUNT OF A BASIC INORGANIC SALT OF MAGNESIUM, CALCIUM, POTASSIUM AND SODIUM | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-06-15 | — | — | US | disclosed |
| US-20030211155-A1 | Stabilized pharmaceutical composition | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-0953584-B1 | Olefin polymer, process for manufacturing the same, curable resin composition, and antireflection coating | JSR CORP (JP) | 2002-12-18 | — | — | EP | disclosed |
| US-6495293-B1 | IMPROVEMENT IN THE DIFFUSIVITY OF ELECTROLYTE; LITHIUM BATTERY | HITACHI, LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| US-20020137771-A1 | Stabilized pharmaceutical composition | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-09-26 | — | — | US | disclosed |
| US-6380234-B1 | HOMOGENITY MIXING, GRANULATION, ENTERIC COATING | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-04-30 | — | — | US | disclosed |
| US-5639478-A | ENTERIC COATING OF A MIXTURE OF AN ANTIULCER AGENT AND ALKALINE METAL SALT STABILIZER | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-06-17 | — | — | US | disclosed |
| EP-0446961-B1 | Stabilized pharmaceutical composition and its production | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-06-19 | — | — | EP | disclosed |
| US-5433959-A | Antisecretory agent such as lansoprazole stabilized by basic inorganic salts | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-07-18 | — | — | US | disclosed |
| EP-0423748-B1 | Stabilized pharmaceutical composition and its production | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-08-24 | — | — | EP | disclosed |
| EP-0237200-B1 | USE OF BASIC INORGANIC SALTS OF MAGNESIUM OR CALCIUM FOR THE STABILISATION OF BENZIMIDAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 1992-07-01 | — | — | EP | disclosed |
| US-5093132-A | Antiulcer benzimidazole derivative with basic alkali metal or alkaline earth metal compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-03-03 | — | — | US | disclosed |
| EP-0446961-A2 | Stabilized pharmaceutical composition and its production | Takeda Chemical Industries, Ltd. (JP) | 1991-09-18 | — | — | EP | disclosed |
| US-5045321-A | Antiulcer compound lansoprazole or omeprazole with magnesium and/or calcium salt; tablets or granules | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-09-03 | — | — | US | disclosed |
| EP-0423748-A1 | Stabilized pharmaceutical composition and its production | Takeda Chemical Industries, Ltd. (JP) | 1991-04-24 | — | — | EP | disclosed |
| EP-0237200-A2 | Use of basic inorganic salts of magnesium or calcium for the stabilisation of benzimidazole derivatives | Takeda Chemical Industries, Ltd. (JP) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137771-A1 | Stabilized pharmaceutical composition | CACNA1E, CA2, CACNA1I | KDM4E 815/4885TSHR 3200/4885TDP1 4370/4885 |
| US-20030211155-A1 | Stabilized pharmaceutical composition | CACNA1E, CA2, CACNA1I | KDM4E 506/4885TSHR 3121/4885TDP1 4302/4885 |
| US-20040209919-A1 | Stabilized pharmaceutical composition | CACNA1E, CA2, CACNA1I | KDM4E 815/4885TSHR 3200/4885TDP1 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.